List View Detail View 276-300 of 435 items Sort by: Best Match Name Clone Applications Regulatory Status Previous 1 ... 11 12 13 ... 18 Next Product Clone Appl. Reg Cat# Size Price Quantity TotalSeq™-B0171 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A PG RUO 313551 10 µg 369 CHF TotalSeq™-C0171 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A PG RUO 313553 10 µg 369 CHF TotalSeq™-D0171 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A PG RUO 313561 10 µg 369 CHF Ultra-LEAF™ Purified anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC, IP, Costim RUO 313539 100 µg 198 CHF 313540 1 mg 633 CHF StarBright UltraViolet 740 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313569 30 µg 130 CHF 313568 150 μg 288 CHF StarBright UltraViolet 795 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313575 30 µg 130 CHF 313570 150 μg 288 CHF Spark PLUS UV395™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313565 25 µg 192 CHF 313566 100 µg 365 CHF Brilliant Violet 785™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313533 25 tests 171 CHF 313534 100 tests 440 CHF Brilliant Violet 605™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313537 25 tests 171 CHF 313538 100 tests 440 CHF Brilliant Violet 750™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313557 25 tests 171 CHF 313558 100 tests 440 CHF Brilliant Violet 421™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313523 25 tests 198 CHF 313524 100 tests 429 CHF Brilliant Violet 510™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313525 25 tests 198 CHF Brilliant Violet 711™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313547 25 tests 198 CHF 313548 100 tests 440 CHF Brilliant Violet 650™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313549 25 tests 198 CHF 313550 100 tests 440 CHF StarBright UltraViolet 740 anti-human/mouse/rat CD278 (ICOS) Basic Panel C398.4A; UCHT1; HIB19; FC RUO 391024 1 kit 415 CHF Results Per Page: 25 50 100 200 Previous 1 ... 11 12 13 ... 18 Next
Follow Us